生物医学工程 |
|
|
|
|
心肌细胞传感器优化设计及其药物分析 |
王琴, 方佳如, 曹端喜, 周洁, 苏凯麒, 黎洪波, 王平 |
浙江大学 生物传感器国家专业实验室 生物医学工程教育部重点实验室
生物医学工程与仪器科学学院,浙江 杭州 310027 |
|
Optimization design and drug analysis of cardiomyocytebased biosensor |
WANG Qin, FANG Jia ru, CAO Duan xi, ZHOU Jie, SU Kai qi, LI Hong bo, WANG Ping |
Biosensor National Special Laboratory, Key Laboratory of Biomedical Engineering of Ministry of Education,
College of Biomedical Engineering and Instrument Science, Zhejiang University, Hangzhou 310027, China |
引用本文:
王琴, 方佳如, 曹端喜, 周洁, 苏凯麒, 黎洪波, 王平. 心肌细胞传感器优化设计及其药物分析[J]. 浙江大学学报(工学版), 10.3785/j.issn.1008973X.2016.06.028.
WANG Qin, FANG Jia ru, CAO Duan xi, ZHOU Jie, SU Kai qi, LI Hong bo, WANG Ping. Optimization design and drug analysis of cardiomyocytebased biosensor. JOURNAL OF ZHEJIANG UNIVERSITY (ENGINEERING SCIENCE), 10.3785/j.issn.1008973X.2016.06.028.
链接本文:
http://www.zjujournals.com/eng/CN/10.3785/j.issn.1008973X.2016.06.028
或
http://www.zjujournals.com/eng/CN/Y2016/V50/I6/1214
|
[1] REDFERN W, CARLSSON L, DAVIS A. et al. Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development [J]. Cardiovascular Research, 2003, 58(1): 32-45.
[2] LAVERTY H, BENSON C, CARTWRIGHT E, et al. How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines [J]. British Journal of Pharmacology, 2011, 163(4): 675-693.
[3] BOWES J, BROWN A J, HAMON J, et al. Reducing safetyrelated drug attrition: the use of in vitro pharmacological profiling [J]. Nature Reviews Drug Discovery, 2012, 11(12): 909-922.
[4] LEXCHIN J. Drug withdrawals from the Canadian market for safety reasons, 19632004 [J]. Canadian Medical Association Journal, 2005, 172(6): 765-767.
[5] MOSS A J, KASS R S. Long QT syndrome: from channels to cardiac arrhythmias [J]. Journal of Clinical Investigation, 2005, 115(8): 2018-2024.
[6] BRAAM S. R, TERTOOLEN L, VAN DE STOLPE A, et al. Prediction of druginduced cardiotoxicity using human embryonic stem cellderived cardiomyocytes [J]. Stem Cell Research, 2010, 4(2): 107-116.
[7] GIORGI M A, BOLANOS R, GONZALEZ C D, et al. QT interval prolongation: preclinical and clinical testing arrhythmogenesis in drugs and regulatory implications [J]. Current Drug Safety, 2010, 5(1): 54-57.
[8] NATARAJAN A, STANCESCU M, DHIR V, et al. Patterned cardiomyocytes on microelectrode arrays as a functional, high information content drug screening platform [J]. Biomaterials, 2011, 32(18): 4267-4274.
[9] HANCOX J C, MCPATE M J, EL HARCHI A. The hERG potassium channel and hERG screening for druginduced torsades de pointes [J]. Pharmacology and Therapeutics, 2008, 119(2): 118-132.
[10] HANSEN A, EDER A, BNSTRUP M, et al. Development of a drug screening platform based on engineered heart tissue [J]. Circulation Research, 2010, 107(1): 35-44.
[11] CHI K R. Revolution dawning in cardiotoxicity testing [J]. Nature Reviews Drug Discovery, 2013, 12(8):565-567.
[12] ABASSI Y A, XI B, LI N, et al. Dynamic monitoring of beating periodicity of stem cell‐derived cardiomyocytes as a predictive tool for preclinical safety assessment [J]. British Journal of Pharmacology, 2012,165(5): 1424-1441.
[13] MANDENIUS C F, STEEL D, NOOR F, et al. Cardiotoxicity testing using pluripotent stem cellderived human cardiomyocytes and stateoftheart bioanalytics: a review [J]. Journal of Applied Toxicology, 2011, 31(3): 191-205.
[14] FERMINI B, FOSSA A A. The impact of druginduced QT interval prolongation on drug discovery and development [J]. Nature Reviews Drug Discovery, 2003, 2(6): 439-447.
[15] XIAO L, HU Z, ZHANG W, et al. Evaluation of doxorubicin toxicity on cardiomyocytes using a dual functional extracellular biochip [J]. Biosensors and Bioelectronics, 2010, 26(4): 1493-1499.
[16] MEYER T, KRAUSHAAR U, GUENTHER E. Microelectrode Array (MEA) high resolution electrophysiological mapping of cardiac cell, tissue and organ preparations [C] ∥ 2009 World Congress on Medical Physics and Biomedical Engineering. Munich: IFMBE, 2009: 112-115.
[17] XU B, JACQUIR S, LAURENT G, et al. Phase space reconstruction of an experimental model of cardiac field potential in normal and arrhythmic conditions [C]∥2013 Annual International Conference of the IEEE.Osaka: IEEE, 2013: 3274-3277.
[18] KORNBLUM A, PILLEKAMP F, MATZKIES M, et al. A new model to perform electrophysiological studies in the early embryonic mouse heart [J]. Cellular Physiology and Biochemistry, 2013, 32(1): 110.
[19] JOHNSTONE A F, GROSS G W, WEISS D G, et al. Microelectrode arrays: a physiologically based neurotoxicity testing platform for the 21st century [J]. Neurotoxicology, 2010, 31(4): 331-350.
[20] CASPI O, ITZHAKI I, KEHAT I, et al. In vitro electrophysiological drug testing using human embryonic stem cell derived cardiomyocytes [J]. Stem Cells and Development, 2009, 18(1): 161-172.
[21] 徐莹,余辉,张威,等.基于 MEMS 技术的微电极阵列细胞传感器 [J].自然科学进展, 2007, 17(9): 1265-1272.
XU Yin, YU Hui, ZHANG Wei, et al. Microelectrode array cell sensor based on MEMS technology [J]. Process in Natural Science, 2007, 17(9): 1265-1272.
[22] KANEKO T, NOMURA F, HATTORI A, et al. Improvement of electrical stimulation protocol for simultaneous measurement of extracellular potential with onchip multielectrode array system [J]. Japanese Journal of Applied Physics, 2012, 51(6S): 06FK02.
[23] GUO L, ABRAMS R M, BABIARZ J E, et al. Estimating the risk of druginduced proarrhythmia using human induced pluripotent stem cellderived cardiomyocytes [J]. Toxicological Sciences, 2011, 123(1): 281-289.
[24] ZOU Y, YAO A, ZHU W, et al. Isoproterenol activates extracellular signalregulated protein kinases in cardiomyocytes through calcineurin [J]. Circulation, 2001, 104(1): 102-108. |
|
Viewed |
|
|
|
Full text
|
|
|
|
|
Abstract
|
|
|
|
|
Cited |
|
|
|
|
|
Shared |
|
|
|
|
|
Discussed |
|
|
|
|